flâneur

Cancer Study Links COVID Shots to Longer Survival | MedPage Today

medpagetoday.com · 724 words · saved by 1 readers

BERLIN -- Non-small cell lung cancer (NSCLC) patients starting immunotherapy were nearly twice as likely to be alive 3 years later if they got a COVID-19 vaccine around the time of treatment, a researcher reported here. Retrospective data in advanced NSCLC found that mRNA COVID vaccination within 100 days of initiating a checkpoint inhibitor was associated with higher 3-year survival rates compared with no vaccination (55.8% vs 30.6%; adjusted HR 0.51, 95% CI 0.37-0.71, P<0.0001), according to Adam Grippin, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston. Analyses in metastatic melanoma mirrored the results, with 3-year survival rates of 67.5% and 44.1%, respectively (adjusted HR 0.34, 95% CI 0.17-0.69, P=0.0029), findings presented at the European Society for Medical Oncology (ESMO) congress opens in a new tab or window showed. Preclinical work from the research team demonstrated how mRNA vaccination can induce a surge in type I interferon-dependent immunity

BERLIN -- Non-small cell lung cancer (NSCLC) patients starting immunotherapy were nearly twice as likely to be alive 3 years later if they got a COVID-19 vaccine around the time of treatment, a researcher reported here. Retrospective data in advanced NSCLC found that mRNA COVID vaccination within 100 days of initiating a checkpoint inhibitor was associated with higher 3-year survival rates compared with no vaccination (55.8% vs 30.6%; adjusted HR 0.51, 95% CI 0.37-0.71, P<0.0001), according to Adam Grippin, MD, PhD, of the University of Texas MD Anderson Cancer Center in Houston. Analyses…

saved by

related reading